Limit search to available items
Book Cover

Title New agents for the treatment of acute lymphoblastic leukemia / Vaskar Saha, Pamela Kearns, editors
Published New York : Springer, ©2011


Description 1 online resource (xviii, 338 pages)
Contents New Agents for the Treatment of Acute Lymphoblastic Leukemia; Brief Overview; Acknowledgements; Contents; Contributors; Glossary; Chapter 1: The Need for New Agents; Chapter 2: Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia; Chapter 3: Preclinical Evaluation; Chapter 4: Design of Early-Phase Trials; Chapter 5: Strategies for Trial Design and Analyses; Chapter 6: An Overview on Animal Models of ALL; Chapter 7: Targeting Bcl-2 Family Proteins in Childhood Leukemia; Chapter 8: Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL
Chapter 9: Nucleoside AnaloguesChapter 10: FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia; Chapter 11: The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL; Chapter 12: Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia; Chapter 13: Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia; Chapter 14: Targeting Epigenetic Pathways in ALL; Chapter 15: Incorporating New Therapies into Frontline Protocols; Index
Summary New Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic. For over 4 decades, no new drugs have been available and now we have a surfeit. The challenge is to design trials to evaluate the potential efficacy of non-targeted therapy in a disease with good outcome. An increasing number of pathways, amenable to targeted therapy are also being identified. The heterogeneity of ALL suggests that targeted therapy at the moment will need to be tailored to the patient. How then can such drugs be evaluated within conventional clinical trials? These are the crossroads we have reached in acute lymphoblastic leukaemia and this book discusses and proposes some solutions to these issues
Analysis neoplasms
biomedische wetenschappen
Medicine (General)
Geneeskunde (algemeen)
Bibliography Includes bibliographical references and index
Notes Print version record
Subject Lymphoblastic leukemia -- Chemotherapy
Drugs -- Design.
Drugs -- Research.
Outcome assessment (Medical care)
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Antineoplastic Agents -- therapeutic use
Clinical Trials as Topic
Treatment Outcome
Drug Design
children (people by age group)
Drugs -- Design.
Drugs -- Research.
Form Electronic book
Author Saha, Vaskar.
Kearns, Pamela
ISBN 9781441984593